IWM
VRDN icon

IHT Wealth Management’s Viridian Therapeutics VRDN Stock Holding History

IHT Wealth Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10
Closed -$1K – 1349
2018
Q1 		$1K Hold
10
– – ﹤0.01% 1645
2017
Q4 		$1K Buy
+10
New +$1.27K ﹤0.01% 1637

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IHT Wealth Management's VRDN Position: Q2 2018 in Review

IHT Wealth Management sold out of Viridian Therapeutics (VRDN) in Q2 2018, closing a stake of 10 shares — an estimated $1K sold.

IHT Wealth Management first reported a position in VRDN in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q1 2018. 59 funds tracked by Wall St. Rank hold VRDN as of Q2 2018.

  • IHT Wealth Management reported no remaining Viridian Therapeutics position as of Q2 2018 after selling out during the quarter.
  • IHT Wealth Management sold 10 Viridian Therapeutics shares in Q2 2018, an estimated $1K.
  • IHT Wealth Management first reported a position in Viridian Therapeutics in Q4 2017 and held it in 2 quarters.
  • IHT Wealth Management's Viridian Therapeutics position peaked at $1K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2018.

Based on IHT Wealth Management's 13F filing for Q2 2018, filed 13 Aug 2018.